[Influence of social support and personality traits on psychological characteristic of patients with chronic cervicodynia and lumbodynia].

OBJECTIVE: To explore the effects of social support and personality traits on psychological characteristic of patients with chronic cervicodynia and lumbodynia and improve the level of diagnosis and treatment. METHODS: From August 2009 to April 2010, 231 patients (obtained 217 effective responses) with chronic cervicodynia and lumbodynia were recruited. Among the patients, there were 123 males and 94 females, with an average age of (38.00 +/- 5.67) years (ranged from 15 to 66 years). Social Support Rating Scale (SSRS), Cattell Sixteen Personality Factor Questionnaire (16PF) and Symptom Checklist 90 (SCL-90) were used to test social support and psychological characteristic and compared the difference of psychological, personality traits and norm, then analyzed the effect of social support and personality traits on psychological characteristic. RESULTS: Two hundred and seventeen (93.9%) patients completed the questionnaire. Compared with normal 16PF scores, there were significant differences in factor scores of intelligence, stability, excitability, perseverance,social boldness, vigilance, sophistication, experimental, independence and tonicity (P < 0.01). And for SCL-90, the score of somatization, depression, anxiety, rivalrounsness, horror, bigotry, total score and mean score were higher than norm (P < 0.01). For SSRS, subjective support points and total points had positive effects; While intelligence, stability, perseverance, self-discipline had positive effects, vigilance and anxiety had negative effects. CONCLUSION: There were significant differences in personality traits and psychological characteristic between patients with chronic cervicodynia and lumbodynia and norms. Improving social support level and optimizing personality traits can improve psychological profile of these patients.

[Early prediction of lamivudine response in e antigen-negative chronic hepatitis B patients].

OBJECTIVE: To evaluate the effects of ALT, HBsAg and HBV DNA at the baseline, 4 and 12 weeks after lamivudine treatment on the long term (104 weeks) response in e antigen-negative chronic hepatitis B patients. METHODS: 127 adult e antigen-negative chronic hepatitis B patients were enrolled in this study. All patients received treatment on LAM 100 mg/d for at least 104 weeks. The liver function, serum HBV markers and HBV viral load were regularly checked during the treatment. The effects of ALT, HBsAg and HBV DNA at the baseline, 4 and 12 weeks after lamivudine treatment on the response at 104 weeks were statistically analyzed. RESULTS: The proportion of patients with serum HBV DNA less than 1000 copies / ml at 104 weeks after LAM treatment was 50.0% and 86.8% in patients with baseline ALT less than 5 ULN and ALT is more than or equal to 5 ULN, respectively (P less than 0.01). In patients with baseline HBsAg less than 2000 COI and HBsAg is more than or equal to 2000 COI, the proportion of patients with serum HBsAg less than 500 COI at 104 weeks after LAM treatment was 19.1% and 17.5%, respectively (P more than 0.05). the HBsAg serological conversion rates were respectively 2.1% and 2.5% , respectively (P more than 0.05), the proportion of patients with serum HBV DNA less than 1000 copies/ml was 61.7% and 67.5%, respectively (P more than 0.05). In patients with baseline HBV DNA less than 10(6) copies/ml and HBV DNA is more than or equal to 10(6) copies/ml, the proportion of patients with HBV DNA less than 1000 copies/ml were statistically different at 4 weeks and 12 weeks after treatment, however, the proportion of patients with HBV DNA less than 1000 copies/ml at 104 weeks after LAM treatment was 62.7% and 67.1%, respectively (P more than 0.05). In patients with HBV DNA less than 1000 copies/ml and HBV DNA is more than or equal to 1000 copies/ml at 4 weeks after treatment, the proportion of patients with HBV DNA less than 1000 copies/ml at 104 weeks after LAM treatment was 70.7% and 60.9%, respectively (P more than 0.05). In patients with HBV DNA less than 1000 copies/ml and HBV DNA is more than or equal to 1000 copies/ml at 12 weeks after treatment, the proportion of patients with HBV DNA less than 1000 copies/ml at 104 weeks after treatment was 78.8% and 38.1%, respectively (P less than 0.01). CONCLUSION: e antigen negative chronic hepatitis B patients with baseline ALT is more than or equal to 5 ULN and HBV DNA less than 1000 copies/ml at 12 weeks after treatment have better virological response at 104 weeks after LAM treatment. The baseline HBsAg and HBV DNA load are associated with the virological response at 104 weeks after LAM treatment.

[Role of gamma delta T cells in the prevention and treatment of allergic bronchial asthma by desensitization of allergen nebulization].

AIM: To explore the role of gammadeltaT cells in the pathogenesis of allergic bronchial asthma. METHODS: Forty patients with Der.p and Der f allergy and partly-controlled asthma were involved in a random study. Besides the fact that all patients were treated with same basic treatment. Patients in group A were nebulized with 5 mL normal saline while group B with specific allergen twice a week for six months. The percentage of gammadeltaT cells in peripheral blood and induced sputum and the percentage of IL-4(+) and IFN-gamma(+) gammadeltaT cells were detected by flow cytometry(FCM) before and after treatment. RESULTS: The percentage of gammadeltaT cells in group B decreased after treatment, and the percentage of IFN-gamma(+) gammadeltaT cells in both peripheral blood and induced sputum increased significantly in group B than that in group A. CONCLUSION: gammadeltaT cells, which may participate in the pathogenesis of bronchial asthma, may contribute to the prevention and treatment of bronchial asthma by desensitization of allergen nebulization.